Advertisement

Medical Oncology

, 32:12 | Cite as

Single-agent bevacizumab is an effective treatment in recurrent glioblastoma

  • Ilhan Hacibekiroglu
  • Hilmi Kodaz
  • Bulent Erdogan
  • Esma Turkmen
  • Melike Ozcelik
  • Asim Esenkaya
  • Haci Mehmet Saygi
  • Sernaz Uzunoglu
  • Irfan Cicin
Original Paper

Abstract

The aim of this study was to evaluate the efficiency and safety of single-agent bevacizumab therapy for recurrent glioblastoma multiforme (GBM). We identified patients with histologically confirmed glioblastoma and World Health Organization Grade III glioma who were previously treated with temozolomide plus radiotherapy and received 10 mg/kg bevacizumab intravenous infusion every 2 weeks until disease progression for recurrent disease. A total 24 patients included to this study. Twenty-two patients had GBM, and two patients had WHO grade III glioma. No complete response was observed, five patients (20.8 %) had partial response, nine patients (37.5 %) had stable diseases, and ten patients (41.7 %) had progressive diseases. The overall response rate was 20.8 %. The 6-month PFS rate (PFS6) and median PFS were determined as 37.5 % and 4.1 months, respectively. Median OS was 6.4 months. Performance status of 17 (70.8 %) patients was improved following bevacizumab regimen. Univariate analysis showed that improvement in performance status (IPS) following bevacizumab therapy was a significant predictor of both PFS (p < 0.001) and OS (p < 0.020). Bevacizumab-related adverse effects were observed in 13 (54.1 %) patients. Grade 3–4 toxicity was observed in 4 (16.6 %) patients. Therapy interruptions were experienced in two patients due to adverse effects. Single-agent bevacizumab is an effective and safe treatment alternative in recurrent GBM. IPS following bevacizumab therapy was a significant predictor of both PFS and OS.

Keywords

Glioblastoma Bevacizumab Single agent 

Notes

Conflict and interest

None.

References

  1. 1.
    Grossman SA, Ye X, Piantadosi S, Desideri S, Nabors LB, Rosenfeld M, et al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res. 2010;16(8):2443–9.CrossRefPubMedCentralPubMedGoogle Scholar
  2. 2.
    Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–66.CrossRefPubMedGoogle Scholar
  3. 3.
    Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.CrossRefPubMedGoogle Scholar
  4. 4.
    Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000;83(5):588–93.CrossRefPubMedCentralPubMedGoogle Scholar
  5. 5.
    Weller M, Cloughesy T, Perry JR, Wick W. Standards of care for treatment of recurrent glioblastoma—Are we there yet? Neuro-Oncology. 2013;15(1):4–27.CrossRefPubMedCentralPubMedGoogle Scholar
  6. 6.
    Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669–76.CrossRefPubMedGoogle Scholar
  7. 7.
    Godard S, Getz G, Delorenzi M, Farmer P, Kobayashi H, Desbaillets I, et al. Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res. 2003;63(20):6613–25.PubMedGoogle Scholar
  8. 8.
    Jain HV, Nor JE, Jackson TL. Modeling the VEGF-Bcl-2-CXCL8 pathway in intratumoral angiogenesis. Bull Math Biol. 2008;70(1):89–117.CrossRefPubMedGoogle Scholar
  9. 9.
    Fang Y, Qu X, Cheng B, Chen Y, Wang Z, Chen F, et al. The efficacy and safety of bevacizumab combined with chemotherapy in treatment of HER2-negative metastatic breast cancer: a meta-analysis based on published phase III trials. Tumour Biol. 2014. doi: 10.1007/s13277-014-2799-7.
  10. 10.
    Lange A, Prenzler A, Frank M, Golpon H, Welte T, von der Schulenburg JM. A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC). BMC Pulm Med. 2014;14(1):192.CrossRefPubMedCentralPubMedGoogle Scholar
  11. 11.
    Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27(5):740–5.CrossRefPubMedCentralPubMedGoogle Scholar
  12. 12.
    Chamberlain MC, Johnston SK. Salvage therapy with single agent bevacizumab for recurrent glioblastoma. J Neurooncol. 2010;96(2):259–69.CrossRefPubMedGoogle Scholar
  13. 13.
    Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733–40.CrossRefPubMedGoogle Scholar
  14. 14.
    Cirillo M, Venturini M, Ciccarelli L, Coati F, Bortolami O, Verlato G. Clinician versus nurse symptom reporting using the National Cancer Institute—common terminology criteria for adverse events during chemotherapy: results of a comparison based on patient’s self-reported questionnaire. Ann Oncol. 2009;20(12):1929–35.CrossRefPubMedGoogle Scholar
  15. 15.
    Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963–72.CrossRefPubMedGoogle Scholar
  16. 16.
    Jansen M, de Witt Hamer PC, Witmer AN, Troost D, van Noorden CJ. Current perspectives on antiangiogenesis strategies in the treatment of malignant gliomas. Brain Res Brain Res Rev. 2004;45(3):143–63.CrossRefPubMedGoogle Scholar
  17. 17.
    Huang H, Held-Feindt J, Buhl R, Mehdorn HM, Mentlein R. Expression of VEGF and its receptors in different brain tumors. Neurol Res. 2005;27(4):371–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58–62.CrossRefPubMedGoogle Scholar
  19. 19.
    Cloughesy T, Prados M, Wen PY. A phase II, randomized, noncomparative clinical trial of bevacizumab alone or in combination with irinotecan prolongs 6-month PFS in recurrent, treatment-refractory glioblastoma [abstract]. J Clin Oncol. 2008;26:2010b.Google Scholar
  20. 20.
    Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25(30):4722–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology. 2006;66(8):1258–60.CrossRefPubMedGoogle Scholar
  22. 22.
    Nagane M, Nishikawa R, Narita Y, Kobayashi H, Takano S, Shinoura N, et al. Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma. Jpn J Clin Oncol. 2012;42(10):887–95.CrossRefPubMedCentralPubMedGoogle Scholar
  23. 23.
    Nghiemphu PL, Liu W, Lee Y, Than T, Graham C, Lai A, et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology. 2009;72(14):1217–22.CrossRefPubMedCentralPubMedGoogle Scholar
  24. 24.
    Francesconi AB, Dupre S, Matos M, Martin D, Hughes BG, Wyld DK, et al. Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme. J Clin Neurosci. 2010;17(8):970–4.CrossRefPubMedGoogle Scholar
  25. 25.
    Hasselbalch B, Lassen U, Hansen S, Holmberg M, Sorensen M, Kosteljanetz M, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro-Oncology. 2010;12(5):508–16.PubMedCentralPubMedGoogle Scholar
  26. 26.
    Sathornsumetee S, Desjardins A, Vredenburgh JJ, McLendon RE, Marcello J, Herndon JE, et al. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro-Oncology. 2010;12(12):1300–10.PubMedCentralPubMedGoogle Scholar
  27. 27.
    Verhoeff JJ, Lavini C, van Linde ME, Stalpers LJ, Majoie CB, Reijneveld JC, et al. Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma. Ann Oncol. 2010;21(8):1723–7.CrossRefPubMedGoogle Scholar
  28. 28.
    Desjardins A, Reardon DA, Coan A, Marcello J, Herndon JE 2nd, Bailey L, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer. 2012;118(5):1302–12.CrossRefPubMedGoogle Scholar
  29. 29.
    Reardon DA, Desjardins A, Peters KB, Gururangan S, Sampson JH, McLendon RE, et al. Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naive, recurrent glioblastoma. J Neurooncol. 2012;107(1):155–64.CrossRefPubMedCentralPubMedGoogle Scholar
  30. 30.
    Raizer JJ, Grimm S, Chamberlain MC, Nicholas MK, Chandler JP, Muro K, et al. A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer. 2010;116(22):5297–305.CrossRefPubMedGoogle Scholar
  31. 31.
    Zhang G, Huang S, Wang Z. A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme. J Clin Neurosci. 2012;19(12):1636–40.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Ilhan Hacibekiroglu
    • 1
  • Hilmi Kodaz
    • 1
  • Bulent Erdogan
    • 1
  • Esma Turkmen
    • 1
  • Melike Ozcelik
    • 2
  • Asim Esenkaya
    • 3
  • Haci Mehmet Saygi
    • 4
  • Sernaz Uzunoglu
    • 1
  • Irfan Cicin
    • 1
  1. 1.Department of Medical Oncology, Faculty of MedicineTrakya UniversityEdirneTurkey
  2. 2.Department of Medical OncologyKartal Training and Research HospitalIstanbulTurkey
  3. 3.Department of Radiology, Faculty of MedicineTrakya UniversityEdirneTurkey
  4. 4.Department of Neurosurgery, Faculty of MedicineTrakya UniversityEdirneTurkey

Personalised recommendations